Core Viewpoint - The company has adjusted the repurchase price of its 2022 restricted stock incentive plan, reflecting changes due to cash dividends and compliance with relevant regulations [5][6][7]. Decision Procedures and Disclosure - The company held board and supervisory meetings to review and approve the adjustment of the repurchase price, ensuring independent opinions were provided by independent directors [1][2]. - The company conducted internal announcements and did not receive any objections during the public notice period [2]. Adjustment Reasons and Results - The adjustment of the repurchase price was necessitated by the distribution of cash dividends of 0.08 yuan per share, which was completed on July 14, 2025 [5][6]. - The repurchase price was adjusted from 11.685 yuan per share to 11.605 yuan per share, in accordance with the incentive plan's provisions [6]. Impact on the Company - The adjustment aligns with the relevant laws and regulations, ensuring no harm to the company or its shareholders, and is not expected to materially affect the company's financial status or operational results [6][7]. Supervisory and Legal Opinions - The supervisory board confirmed that the adjustment complies with the necessary legal frameworks and does not harm the interests of the company or its shareholders [7]. - Legal opinions from Hunan Qiyuan Law Firm affirmed that the adjustment has received the required approvals and adheres to relevant regulations [7].

Group 1 - The company announced the repurchase and cancellation of 1,205,377 restricted stocks from its 2022 incentive plan due to 32 individuals leaving for personal reasons and performance not meeting standards [1] - Following the repurchase, the company's registered capital will decrease by 1,205,377 yuan [1] - Creditors have a 30-day period from receiving the notice, or 45 days from the announcement date, to claim debts or request guarantees [1][2] Group 2 - Creditors must submit written requests along with relevant documentation to the company to claim debts or seek guarantees [2]

Core Viewpoint - The company has decided to repurchase and cancel a total of 1,205,377 restricted shares from its 2022 incentive plan due to the departure of 32 employees and underperformance in meeting company-level targets [1][7][8] Summary by Sections 1. Background of the Repurchase - The company held meetings on August 25, 2025, where the board and supervisory committee approved the repurchase of remaining restricted shares from the 2022 incentive plan [1] - The total amount for the repurchase is 14,889,399.25 yuan, sourced from the company's own funds [6] 2. Details of the Incentive Plan - The 2022 incentive plan included provisions for the approval and implementation of the plan, which was publicly disclosed and reviewed by independent directors [2][3] - The plan faced adjustments due to the departure of employees and performance issues, leading to the decision to cancel the restricted shares [5][7] 3. Repurchase Details - The repurchase involves 1,205,377 shares, with a repurchase price of 11.605 yuan per share, which includes interest from the People's Bank of China [6] - The repurchase will not affect the company's financial status or operational results significantly [7] 4. Impact on Share Structure - Following the repurchase, the company's total share structure will change, with the number of restricted shares decreasing to zero, while the number of unrestricted shares remains at 758,890,236 [6] 5. Future Actions - The company will proceed with necessary legal and regulatory procedures related to the repurchase and will ensure timely disclosure of information [8]

本律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》、《上市公司股东会规则》（以下简称"《股东会规则》"） 等我国现行法律、法规、规范性文件以及《益丰大药房连锁股份有限公司章程》 （以下简称"《公司章程》"）的有关规定出具本法律意见书。 本所及经办律师依据《证券法》、《律师事务所从事证券法律业务管理办法》 和《律师事务所证券法律业务执业规则》等规定及本法律意见书出具日以前已经 发生或者存在的事实，严格履行了法定职责，遵循了勤勉尽责和诚实信用原则， 进行了充分的核查验证，保证本法律意见所认定的事实真实、准确、完整，所发 表的结论性意见合法、准确，不存在虚假记载、误导性陈述或者重大遗漏，并承 担相应法律责任。 关于益丰大药房连锁股份有限公司 法律意见书 二O二五年八月 致：益丰大药房连锁股份有限公司 湖南启元律师事务所（以下简称"本所"）接受益丰大药房连锁股份有限公 司（以下简称"公司"）的委托，指派本律师出席了公司 2025 年第二次临时股东 会（以下简称"本次股东会"），对本次股东会的召集和召开程序、出席会议人 员及召集人的资格、表决程序和表决结果的合法有效性进行现场律师见 ...

金融界消息 截至2025年8月25日收盘，益丰药房（603939）报收于24.13元，下跌1.67%，换手率 1.24%，成交量15.05万手，成交金额3.62亿元。 资金流向方面，今日主力资金净流出5898.46万元，占比成交额16.28%。其中，超大单净流出3851.99万 元、占成交额10.63%，大单净流出2046.48万元、占成交额5.65%，中单净流出流入1805.76万元、占成 交额4.98%，小单净流入4092.70万元、占成交额11.3%。 来源：金融界 天眼查商业履历信息显示，益丰大药房连锁股份有限公司，成立于2008年，位于常德市，是一家以从事 卫生为主的企业。企业注册资本121243.2297万人民币，实缴资本12000万人民币。公司法定代表人为高 毅。 通过天眼查大数据分析，益丰大药房连锁股份有限公司共对外投资了33家企业，参与招投标项目1316 次，知识产权方面有商标信息311条，专利信息6条，此外企业还拥有行政许可126个。 益丰药房最新一期业绩显示，截至2025一季报，公司营业总收入60.09亿元、同比增长0.64%，归属净利 润4.49亿元，同比增长10.51%，扣非净利润4 ...

8月25日下午，益丰药房发布公告称，公司近日收到公司副总裁章佳的书面辞职报告。章佳因个人原因 申请辞去公司副总裁职务，辞职后不再担任公司其他任何职务。据悉，章佳于2024年6月25日期担任益 丰药房副总裁一职，原定任期到期日2027年6月24日。2024年年报显示，章佳2024年年末持有16.80万 股，2024年从公司获得的税前报酬为159.26万元。 2025年一季度，益丰药房新增门店94家，其中，自建门店26家，加盟店68家。另，关闭门店84家。截至 2025年一季度期末，公司门店总数1.47万家（含加盟店3880家），较上期末净增门店10家。 章佳于1981年11月出生，曾任沃尔玛中国采购部价格经理，屈臣氏中国采购部总监、护肤品采购负责 人，有生品见（南京）有限公司CMO，广州哆啦科技有限公司(fordeal)供应链副总裁，益丰药房副总 裁。 益丰药房主要经营模式包括商品采购、物流配送、仓储管理和门店销售等业务流程。2025年一季度，益 丰药房实现营收60.09亿元，同比增长0.64%；实现归母净利润4.49亿元，同比增长10.51%。 ...

本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 大股东持股的基本情况 本次减持计划实施前，老百姓医药集团有限公司（以下简称"医药集团"）作为老百姓大药房连锁股份有 限公司（以下简称"公司"）控股股东，持有公司股份198,564,175股，占当时公司总股本的26.12%。 ● 减持计划的实施结果情况 2025年5月7日，公司披露了《股东减持股份计划公告》（公告编号：2025-025），医药集团计划以集中 竞价和大宗交易方式减持公司股份合计不超过22,802,868股，即不超过公司股份总数的3%。其中集中竞 价减持股份的总数不超过公司总股本的1%，大宗交易方式减持股份的总数不超过公司总股本的2%。 在本次减持计划实施期间，医药集团于2025年6月20日、6月23日、7月30日通过集中竞价交易和大宗交 易方式合计减持公司股份18,110,700股，占公司总股本的2.38%，截至本公告披露日，医药集团持有公 司股份180,453,475股，占公司目前总股本的23.74%，控股股东医药集团及其一致行动人陈秀 ...

Group 1 - The company held the 14th meeting of the 5th Supervisory Board on August 14, 2025, in Changsha, Hunan Province, with all three supervisors present and voting [1][2][3] - The meeting was convened and chaired by Mr. Chen Bin, the chairman of the Supervisory Board, and all resolutions passed were deemed legal and effective [1][3] - The Supervisory Board approved a proposal for the wholly-owned subsidiary, Hubei Yifeng Pharmacy Chain Co., Ltd., to apply for a bank credit limit, which is subject to bank approval and can be reused within the credit period [2]

Group 1 - The company announced an increase in temporary proposals for the second extraordinary general meeting of shareholders scheduled for August 25, 2025 [1][2] - The proposal to be added is regarding the company's guarantee for a subsidiary's bank credit application, submitted by a major shareholder holding 19.88% of the shares [2][3] - The original notice of the shareholders' meeting remains unchanged aside from the added proposal [2][3] Group 2 - The meeting will take place at 14:30 on August 25, 2025, at the company's logistics park in Changsha, Hunan Province [2][3] - Online voting will be available through the Shanghai Stock Exchange's system on the same day, with specific voting time slots outlined [2][3] - The equity registration date for the shareholders' meeting remains unchanged [3]

Core Viewpoint - The announcement details a significant equity change involving the major shareholder of Yifeng Pharmacy, indicating a reduction in shareholding through a block trade, which does not affect the company's control structure or governance [3][4][5]. Group 1: Shareholder Information - The major shareholder, Ningbo Meishan Bonded Port Area Houxin Venture Capital Partnership (Limited Partnership), along with its concerted actions, has reduced its shareholding from 34.85% to 32.85% [3][4]. - The reduction involved the sale of 24,248,200 shares, representing 2.00% of the company's total equity [3][9]. Group 2: Reduction Plan Details - Prior to the reduction, the controlling shareholder held 262,492,776 shares, accounting for 21.65% of the total equity, while its concerted action partners held additional shares [8][9]. - The reduction was part of a previously disclosed plan and was executed between August 5 and August 6, 2025, through block trading [3][9]. Group 3: Compliance and Impact - The equity change complies with relevant laws and regulations, including the Securities Law of the People's Republic of China and the Shanghai Stock Exchange listing rules [5]. - The reduction will not lead to any changes in the company's controlling shareholder or actual controller, nor will it significantly impact the company's governance or ongoing operations [4][5].